‘Truly Remarkable’ Results Spur Incannex’s Phase 2/3 Trials for Sleep Apnea Drug Candidate, Says CEO
As Incannex advances IHL-42X, a cannabinoid combination product, into phase 2/3 clinical trials for treating OSA, CEO Joel Latham praises early trial outcomes, signaling strong potential for the drug’s marketability.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
